We're transforming Alaska's hometown airport into the West Coast's premier global gateway We're planning for at least 12 international destinations with long-haul aircraft from Seattle by 2030 Nonstop transpacific flights between Seattle and Seoul Incheon begin in September SEATTLE , May 12, 2025 /PRNewswire/ -- Alaska Airlines celebrates a new global connection between the Pacific Northwest and Japan with an inaugural flight today between our hometown hub in Seattle and Tokyo Narita, operated by Hawaiian Airlines' long-haul aircraft. The new service marks the start of daily nonstops between the two dynamic cities and the beginning of a new era of …

OAKVILLE, Ontario--(BUSINESS WIRE)--FCT, Canada's leading provider of title insurance and real estate technology, today announced an agreement with Interac Corp. (Interac) to integrate the Interac Verified™ credential service into FCT's real estate technology solutions. The agreement and pending integration set the stage for broader adoption of secure and reusable digital identity credentials across the Canadian real estate ecosystem, marking a major step toward a national standard for digitall.

SANTA CLARA, Calif., & MUNICH--(BUSINESS WIRE)--Cerabyte, the pioneer of ceramic-based data storage solutions, today announced a strategic investment from Western Digital Corp. (NASDAQ: WDC), a leading developer and manufacturer of storage solutions, including hard disk drives. The partnership will accelerate the development of Cerabyte's ground-breaking ceramic data storage technology, designed to meet the growing demand for permanent accessible long-term data storage in existing and new use c.

ATLANTA--(BUSINESS WIRE)--Atlanta Braves Holdings, Inc. (“ABH”) (Nasdaq: BATRA, BATRK) today reported first quarter 2025 results. Headlines include: Total revenue grew to $47 million in the first quarter of 2025, up 27% from the prior year period. Baseball revenue increased 30% from the prior year period to $29 million. Mixed-use development revenue grew 23% from the prior year period to $19 million. Mixed-Use Development generated $13 million of Adjusted OIBDA(1) in the first quarter of 2025,.

Q1 revenues increased 412% year over year, driven by AI Nose products Delivers strong turnaround from gross loss to gross profit in Q1 AI Nose gains traction beyond healthcare with strategic partnerships in robotics and semiconductor sectors VELDONA® program advances with TFDA and IRB Approvals for two clinical trials in Taiwan SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 12, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "Q1 2025 represents …

First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J.

BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that data from its First-In-Human Phase 1/2a MUSIC-HFpEF clinical trial investigating its adeno-associated virus-based gene therapy candidate SRD-002 in heart failure with preserved ejection fraction (HFpEF) will be presented at the upcoming Heart Failure 2025 Congress taking place May 17-20, 2025, in Belgrade, Serbia.

BEIJING, CHINA / ACCESS Newswire / May 12, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has entered into a definitive Equity and Assets Transfer Agreement (the "Equity and Assets Transfer Agreement") with Kaixin Pharmaceuticals Inc. ("Kaixin Pharmaceuticals"), a Cayman Islands incorporated entity wholly-owned by Dr. Wei-Wu He, Chairman of the board of directors and CEO of the Company and two direct wholly-owned subsidiaries of the Company in China (the "Target Companies"), pursuant to which the Company shall sell …

Innovative pilot project highlights the role of thermal energy storage in decarbonizing public institutions Pilot installations offer replicable frameworks for wider adoption Brenmiller's bGen™ intended to reduce 550 metric tons of CO2 emissions annually The project and its key findings will be presented in a webinar on May 19, 2025 hosted by the Renewable Thermal Collaborative TEL AVIV, IL / ACCESS Newswire / May 12, 2025 / Brenmiller Energy Ltd. ("Brenmiller", "Brenmiller Energy" or the "Company") (Nasdaq:BNRG), a leading global provider of thermal energy storage ("TES") solutions for industrial and utility customers, announced today the publication of a joint case …

~ Advanced Preparation for New Drug Application ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced it has added Tracy Hysong, CCRA as Senior Director of Regulatory Affairs to its management team. Ms. Hysong is a Certified Clinical Research Associate (CCRA) through the Association of Clinical Research Professionals with years of experience undertaking regulatory activity at the University of California Davis (UC Davis).

Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today addresses frequently asked stockholder questions regarding a reverse stock split proposal at the Company's Annual Meeting taking place on Wednesday, May 21, 2025, to regain Nasdaq compliance.

LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S.

Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent …

I see value in the Energy sector due to its recent underperformance, expected demand rise, and potential trade clarity boosting crude oil prices. Crude oil demand is set to increase, making the current sell-off an opportunity to buy into undervalued Energy ETFs like VDE and IXC. The US's reliance on international trade and a weakening USD could further support crude oil prices, benefiting the Energy sector.

Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio's proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment.

SAN MATEO, Calif.--(BUSINESS WIRE)--Backblaze, Inc. (Nasdaq: BLZE), the cloud storage innovator providing a modern alternative to traditional cloud providers, today announced participation in the following investor conference: 20th Annual Needham Technology, Media & Consumer Conference, New York, NY. Gleb Budman, CEO of Backblaze, will participate in a fireside chat on Tuesday, May 13, 2025, at 3:45 p.m. ET The fireside chat will be webcast live. Links to the live and archived webcast will.

MONTREAL, May 12, 2025 (GLOBE NEWSWIRE) -- Tracy Robinson, President and Chief Executive Officer of CN (TSX: CNR) (NYSE: CNI), will address the 18th Annual Wolfe Research Global Transportation & Industrials Conference on May 20, 2025, starting at 8:00 a.m. Eastern Time (ET).

HUNTSVILLE, Ala.--(BUSINESS WIRE)-- #5G--Adtran today announced its new AI Network Cloud (AINC)-interconnect solution, a next-generation fiber networking platform designed to support hyperscalers, federal agencies, SLED organizations and enterprises as they scale AI services. Integrating with Dell's AI Factory, the technology dynamically adjusts optical networking capacity to meet real-time AI workloads, enabling seamless, high-speed connectivity from data center to data center and from core to edge.

SEATTLE--(BUSINESS WIRE)--(NASDAQ: RDFN) — The typical home bought in the U.S. hit a record age of 36 years in 2024, according to a new report from Redfin (redfin.com), the technology-powered real estate brokerage. That's nine years older than the median age of homes purchased in 2012, highlighting how a lack of new construction over the past 15 years has fast-tracked the aging of America's housing stock. This is according to a Redfin analysis of MLS data on the age of homes bought between 2012.

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2025, and provided an overview of recent developments. “We are entering a pivotal and exciting period for UroGen as we approach the anticipated FDA approval of our lead pipeline product, UGN-102, in June for recurrent low-grade in.